A b s t r a c t e capacities of di erentiation of Mycobacterium bovis BCG from other members of M. tuberculosis complex species using PCR-RFLP, multiplex PCR, and PCR-based genomic deletion analysis approaches were compared. In the study, mycobacteria isolated from patients suspected of adverse events following vaccination with BCG, primarily classified according presence of RD1 marker as virulent and avirulent mycobacteria, were used. e PCR-based genomic deletion analysis was found the best option for mycobacteria diagnostics improvement, as it was capable precisely di erentiate virulent and avirulent mycobacteria or virulent species of M. tuberculosis complex.
Introduction
Although extensive studies have been performed to develop advanced vaccines against tuberculosis (TB), vaccination with attenuated Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only commercially available vaccine against TB (WHO, 2011) . e BCG vaccine is used worldwide (Brewer, 2000) and generally is regarded as being the safest in use, but the real incidence of disease evoked by BCG strains, e.g. BCG-itis or osteitis, is not known (Behr, 2002) . Localized abscesses, regional lymphadenopathy, and disseminated disease in immunocompromised hosts are generally regarded as rare but well recognized complications following BCG vaccination (Bernatowska et al., 2007) . Abscesses at BCG injection sites and in places other than BCG injection sites have also been described in healthy hosts (Pankowska and Rożniecki, 1997; Gołębiowska et al., 2008) . In Poland, BCG vaccination has been a part of the National Immunization Program since 1951, and currently involves a single BCG dose given to neonates only. BCG AEFI (Adverse Events Following Immunization) cases are registered through passive surveillance and most of them are not routinely confirmed in the laboratory. e rate of AEFI in Poland is regarded as low (Szczuka, 2002) , however, lack of simple and routine diagnostics does not allow to estimate its real incidence. Lack of routinely used species--specific diagnostics also complicates fast and reliable diagnosis of mycobacteria grown from BCG vaccinated individuals su ering from immunodeficiencies. e M. tuberculosis complex consists of mycobacteria characterized by high DNA-DNA homology (from hybridization studies) and identical 16S rRNA sequences but di er in phenotypes and pathogenicity.
is group has consisted of seven closely related species: M. tuberculosis -infecting human and primates; M. africanum, a heterogeneous group causing human tuberculosis in Africa; M. microti, found as a source of infection in voles and very rarely in immunocompromised humans; M. bovis, causing tuberculosis in cattle and a wide variety of other animals, including man; M. bovis Bacille Calmette-Guérin (BCG), an attenuated vaccine strain; M. canetti, a very rare, smooth variant of M. tuberculosis, usually isolated in Africa; and M. caprae, primarily causal agent of caprine TB with transmission to human and wild animals reported (Brosch et al., 2002; Cousins et al., 2003; Rodríguez (Cousins et al., 2003) and M. orygis, causative agent of tuberculosis in oryxes, gazelles, and waterbucks in Africa; cows and rhesus monkeys in South Asian; and humans (van Ingen et al., 2012) . It has been estimated that as many as 49 BCG substrains might be used in the world (Corbel et al., 2004) since the original Bacille Calmette-Guérin attenuated strain has been distributed worldwide. BCG daughter strains were found heterogenic as the result of the microevolution due to specific production processes, which can be currently specifically identified with molecular tools (Behr, 2002) . e use of reliable molecular tools applicable for confirmation of species identity in AEFI suspected cases are expected to precisely identify all M. tuberculosis complex representatives together with a possibility to identify M. bovis BCG substrains. In order to evaluate the capacities of molecular diagnostic tools described previously as potentially applicable for M. tuberculosis complex identification, in this pilot study we have used reference mycobacteria species and randomly chosen mycobacteria isolates grown from AEFI suspected cases and collected at the National Tuberculosis and Lung Diseases Research Institute (NTLDRI). e mycobacteria isolated from patients and chosen for the purpose of the study have been primarily classified as virulent and avirulent mycobacteria, as they were found habour and not harbour RD1 marker, respectively. ree potentially applicable variants of PCR-based methods involving di erent species-specific or substrain-specific sequences published previously were introduced for testing and compared.
Experimental Material and Methods
Strains. A total of 10 mycobacterial strains isolated from BCG AEFI suspected cases within 2004-2010, have been included in the study. At NTLDRI they were diagnosed as virulent (7575, 3221, 1339, 5995, 5379) and avirulent (60, 4138, 868, 1078, 2714) mycobacteria according PCR performed with primers specific for RD1 region (Talbot et al., 1997 DNA extraction. Chromosomal DNA was isolated from mycobacterial strains as described by van Soolingen et al. (1991) .
PCR.
In the study we have tested PCR-RFLP developed by Kasai et al. (2000) , PCR-based genomic deletion analysis described by Warren et al. (2006) and multiplex PCR developed by Bedwell et al. (2001) . System developed by Kasai et al. (2000) involved restriction of amplified product of the partial gyrB gene with RsaI or TaqI enzymes. PCR-based genomic deletion analysis involved PCR method with use of primers specific for RD1, RD4, RD9, and RD12 regions (Warren et al., 2006) . In a multiplex PCR described by Bedwell et al. (2001) primers specific for RD1, RD2, RD8, RD16 and the senX3-regX3 regions were primarily developed for purposes of identification of di erent substrains of M. bovis BCG.
Results
Among 10 mycobacteria isolates, 5 primarily classified at the NTLDRI as avirulent mycobacteria (60, 4138, 868, 1078, 2714) , were easily identified as M. bovis BCG Moreau isolates (Fig. 1A) as they showed a multiplex-PCR profiles presence of 196 bp (ΔRD1), 252 bp (RD14), 276 bp (senX3-regX3), 315 bp (RD2) and the 472 bp (RD8) amplified fragments. Multiplex-PCR profiles of reference M. bovis BCG Danish and M. bovis BCG Tokyo substrains according of size of amplified fragments were easily di erentiated from M. bovis BCG Moreau substrain. Other 5 mycobacteria isolates, classified at the NTLDRI as virulent (7575, 3221, 1339, 5995, 5379) , presented profiles di erent from those of M. bovis BCG reference strains and samples of avirulent mycobacteria. In the profiles of mycobacteria samples, pre-classified as virulent, there were found products seen in the profiles of all M. tuberculosis complex reference strains. e amplification profiles of virulent mycobacteria samples were composed of fragments RD1 (146 bp), RD14 (252 bp), RD2 (315 bp), RD16 (401 bp), RD8 (472 bp) regions but did not contained the PCR product expected for the senX3-regX3 region. As multiplex PCR profiles did not contained 352 bp and/or 276 bp products, single PCR reactions were performed with senX3-regX3 region primers revealing their presence and suggesting the inhibition of the PCR reaction in cases of the virulent mycobacteria isolates (Fig. 1B) .
During the PCR-based genomic deletion analysis, 5 isolates classified at the NTLDRI as avirulent mycobacteria (60, 4138, 868, 1078, 2714) , were easily identified as M. bovis BCG (Fig. 1C) In the first step of PCR-RFLP gyrB analysis unique sequence for M. tuberculosis complex was amplified. Fragment of 1 020 bp was present in all mycobacteria strains used in the study (data not shown) and confirmed affiliation to the M. tuberculosis complex. At the second step, the amplified DNA fragments were digested by RsaI or TaqI and enabled four species of M. tuberculosis, M. africanum, M. bovis and M. microti to be di erentiated. As shown in the Fig. 1D , M. bovis and M. microti could be di erentiated from the other species by the presence of RsaI-digested fragments of 500 bp and 700 bp, respectively. TaqI digestion of the partial gyrB gene generated a 300 bp-fragment specific for M. tuberculosis as described Kasai et al. (2000) but also for M. canetti.
Discussion
e adverse events following vaccination with BCG, although registered by national surveillance a er clinical recognition, are confirmed in the laboratory rarely. Moreover, the di erentiation of M. bovis BCG from other members of the M. tuberculosis complex has previously been regarded difficult (Augustynowicz--Kopeć et al., 2006). Some variants of NAT (Nucleic Acid Amplification Techniques) have been described in order to improve M. tuberculosis complex or M. bovis BCG substrains diagnostics possibilities (Jagielski et al., 2010a (Jagielski et al., , 2010b . In our study we have compared diagnostics capacity of gyrB-based PCR-RFLP, multiplex PCR, and PCR-based genomic deletion analysis using a set of reference mycobacteria strains and ten mycobacteria isolates originating from BCG AEFI suspected cases collected at the NTLDRI. e first one -the gyrB-based PCR-RFLP method, previously shown to be useful for di erentiation of closely related strains of bacteria such as Vibrio (Venkateswaran et al., 1998) and Bacillus spp. (Yamada et al., 1999) , was adopted by Kasai et al. (2000) to identify four M. tuberculosis complex members (M. tuberculosis, M. bovis, M. africanum and M. microti). In our study, although proper restriction profiles for all above mentioned four species were observed, the system failed to di erentiate M. bovis BCG substrains, M. bovis BCG from virulent M. bovis, and M. tuberculosis from M. canetti species. e multiplex PCR described by Bedwell et al. (2001) easily distinguished M. bovis BCG substrains, however failed to di erentiate M. tuberculosis, M. africanum, M. canetti, and M. pinnipedii species. us, M. bovis BCG Moreau substrain was easily identified in all isolates, determined at the NTLDRI as avirulent ones, however without the value for species identification in virulent isolates.
PCR-based genomic deletion analysis (Warren et al., 2006) , described originally as accurate tool for identification of M. canetti, M. tuberculosis, M. africanum, M. microti, M. pinnipedii, M. caprae or M. bovis BCG species, was found the most potent diagnostics option. Regions of di erences distinguished M. bovis, M. bovis BCG, M. tuberculosis, M. canetti, M. microti and M. africanum species were described previously (Brosch et al., 2002) . Di erentiation of M. microti/africanum/pinnipedii species was possible with a second PCR round with additionally designed primers. Although, PCR-RFLP of the partial gyrB gene (Kansai et al., 2000) and multiplex PCR (Bedwell et al., 2001 ) methods declared improvement of diagnostics potential, only PCR-based genomic deletion analysis developed by Warren et al. (2006) , was found capable to precisely and simultaneously di erentiate virulent and avirulent mycobacteria or virulent species of M. tuberculosis complex. Multiplex PCR developed by Bedwell et al. (2001) was found a valuable diagnostic option in situations when information on the M. bovis BCG substrain might be needed, eg. in foreigners infected with M. bovis BCG.
e criteria for the diagnosis of disseminated BCG infection in people with primary immunodeficiency, including definitive cases confirmed as M. bovis BCG substrain infection by culture and/or standard PCR (Bernatowska et al., 2007) were previously proposed. However, the diagnostic details were not evaluated and discussed. As many di erent molecular tools were described, their evaluation is expected to improve AEFI surveillance measures. PCR-based genomic deletion analysis might be thus chosen for purposes of rapid identification of mycobacteria carriers, appropriate treatment of patients, epidemiological studies purposes, transmission studies of M. bovis between animals and humans, reliable confirmation of M. bovis BCG recovered from immunocompromised patients and healthy individuals suspected of AEFI a er BCG vaccination.
